AI-generated research brief — verify at source
Ad5-Vectored COVID-19 Vaccine Shows No Increased HIV Acquisition Risk in Large Phase 3 Trial
In a Phase 3 randomised controlled trial of 43,780 participants, HIV incidence over six months post-vaccination was 0.29% in those who received the Ad5-nCoV vaccine compared with 0.21% in the placebo group — a numerically small difference that did not indicate elevated risk from vaccination. Importantly, the presence of pre-existing adenovirus type 5 neutralising antibodies did not further elevate HIV acquisition risk in either group.
What Was Studied
This analysis examined whether vaccination with Ad5-nCoV — a COVID-19 vaccine using an adenovirus type 5 (Ad5) viral vector — increases the risk of acquiring HIV infection, including whether pre-existing Ad5 neutralising antibodies (Nab) modify that risk. The question carries particular significance because Ad5-vectored platforms have previously raised theoretical concerns about facilitating HIV entry into immune cells primed by prior Ad5 exposure.
How It Was Studied
Researchers conducted a secondary analysis within a double-blind, randomised, placebo-controlled Phase 3 trial (NCT04526990) that ran from September 2020 to March 2021 across 66 clinical sites in Argentina, Chile, Mexico, Russia, and Pakistan. A total of 43,780 HIV-negative adults were included after excluding participants without valid baseline HIV test results. Participants were initially randomised 1:1 to receive either a single dose of Ad5-nCoV or placebo; in a subsequent crossover phase, placebo recipients received one dose of Ad5-nCoV and original vaccine recipients received a second dose approximately 6–10 months later. HIV status was assessed by self-report at enrolment and confirmed by testing of a baseline blood sample, with HIV incidence tracked over a six-month window following vaccination. Pre-existing Ad5 Nab levels were assessed in approximately 100 randomly selected participants per country.
What Was Observed
- Baseline HIV prevalence was virtually identical between groups: 0.39% of 21,877 participants in the placebo group and 0.38% of 21,893 participants in the Ad5-nCoV group tested HIV-positive prior to vaccination, with no meaningful difference when stratified by country, sex, age, or race.
- Post-vaccination HIV incidence was low and comparable across all groups: Over six months, incidence was 0.29% in the primary Ad5-nCoV group (Group A) versus 0.21% in the placebo group (Group B). Among participants who ultimately received two doses of Ad5-nCoV (Group C), incidence was notably lower at 0.10%, and the pooled group receiving at least one dose of Ad5-nCoV showed an incidence of 0.25%.
- Pre-existing Ad5 neutralising antibody levels were similar across countries and did not increase HIV risk: The proportion of participants with Ad5 Nab titres above 200 ranged narrowly from 65.42% to 67.71% across the five countries. Elevated pre-existing Ad5 Nab titres were not associated with any increase in HIV acquisition, directly addressing a key mechanistic concern about this vaccine platform.
Why This Matters
Concerns about Ad5-vectored vaccines and HIV acquisition risk have been a recurring safety question for this class of vaccine platforms, and resolving this question with large-scale controlled trial data is scientifically important. This study provides direct evidence from a geographically and demographically diverse population — including countries with varying background HIV prevalence — that Ad5-nCoV does not appear to elevate short-term HIV acquisition risk. The finding also specifically addresses the role of pre-existing Ad5 immunity, which had been hypothesised as a potential risk-modifying factor.
How to Read This Result
While the trial was large and well-controlled, the six-month follow-up period limits conclusions about whether any differential HIV acquisition risk might emerge over a longer timeframe, and the crossover design — in which placebo recipients eventually received Ad5-nCoV — reduces the duration of the blinded controlled comparison.
Limitations
HIV status at enrolment relied partly on participant self-report, with laboratory confirmation limited to a single baseline blood draw rather than prospective longitudinal testing. The follow-up period of approximately six months post-vaccination may be insufficient to detect HIV acquisition risk that could manifest over a longer horizon. Additionally, because participants originally assigned to placebo subsequently received Ad5-nCoV, the controlled comparison phase was effectively time-limited, constraining the ability to draw conclusions about cumulative or long-term risk differences between vaccinated and unvaccinated individuals.